We have studied adipose tissues and circulating parameters in mice bearing the HIV-1 transgene as a model to provide insight into the role of HIV-1-infection-related events in fat alterations. Methods: Heterozygous transgenic mice expressing a 7.7 kb HIV-1 construct (Tg26+/-) were used. Cytokine and adipokine levels were quantified using multiplex procedures. Gene expression and mitochondrial DNA abundance in visceral and subcutaneous white adipose tissues and in brown fat were determined using quantitative real-time PCR. Results: The amount of visceral, but not subcutaneous, adipose depot was lower in Tg26+/-mice. Serum proinflammatory cytokine levels were increased in Tg26+/-mice, whereas adiponectin and leptin levels were reduced. Gene expression of monocyte chemoattractant protein-1 was induced in visceral and subcutaneous fat, whereas tumour necrosis factor-α and interleukin-6 were induced in visceral and subcutaneous white adipose tissues, respectively. Adiponectin and leptin gene expression was repressed in all white fat depots, in concert with reduced expression of peroxisome proliferator-activated receptor γ, a master controller of adipogenesis. In brown fat, a coordinate induction in the expression of thermogenesis marker genes was observed. Conclusions: HIV-1 transgene expression in mice causes changes in adipose tissue reminiscent of those in patients with HIV-1 lipodystrophy, particularly early pretreatment changes. These data support a role for HIV-1-infectionrelated events in eliciting adipose tissue dysfunction. The Tg26+/-mouse appears as a promising model to assess the effects of HIV-1 infection on adipose tissue and for determining the effects of antiretroviral drugs on an HIV-1-infected background.
A substantial number of HIV type-1 (HIV-1)-infected patients undergoing antiretroviral treatment develop HIV-1/antiretroviral treatment-associated lipodystrophy syndrome (HALS). HALS is characterized by lipoatrophy in subcutaneous adipose tissue, visceral obesity and lipomatosis [1] , as well as systemic metabolic alterations, including insulin resistance, hypoadiponectinaemia and dyslipidemia. HALS has a complex causal origin. Antiretroviral drugs promote lipoatrophy and systemic metabolic disturbances, but there is growing evidence that events elicited directly by HIV-1 infection contribute to the development of the syndrome. Mild alterations of adipose tissue distribution and gene expression appear in HIV-1-infected, untreated (treatment-naive) patients [2, 3] . In addition, HIV-1 infection in the absence of antiretroviral treatment might cause hypertriglyceridaemia and enhanced lipolysis [4] .
Rodent models of HIV-1-associated lipodystrophy are scarce and treatment of wild-type mice with antiretroviral drugs has been shown to cause minor Introduction alterations in adipose tissue [5, 6] . In addition, there is little information on the effect of HIV-1 infection on adipose tissue alterations and lipodystrophy in rodent models. A single report indicated that transgenic mice expressing the HIV-1 accessory viral protein R in liver and adipose tissues exhibit altered systemic lipid metabolism [7] . Transgenic mice expressing a 7.7 kb HIV-1 construct lacking the gag-pol genes region (Tg26 mice) have proven useful for studying disturbances associated with HIV-1 infection. Homozygous Tg26 mice exhibit an extreme phenotype that includes wasting syndrome and early mortality; however, heterozygous Tg26 mice (Tg26+/-) show normal growth and their primary phenotypic abnormalities are nephropathy and skin lesion in adults [8] . Here, we analysed Tg26+/-mice for adipose tissue disturbances and related systemic alterations. Our focus was to assess whether HIV-1-infectionrelated events cause alterations similar to lipodystrophy and also to evaluate the potential utility of the Tg26+/-mouse as a model for HIV-1-infection-mediated adipose tissue alterations and lipodystrophy syndrome.
Methods
Mice were used in accordance with the European Community directive 86/609/EEC. Ten-week-old male Tg26+/-mice and wild-type littermates were killed by decapitation, and epididymal white adipose tissue (WAT) representative of visceral, intra-abdominal fat (vs-WAT), dorsal subcutaneous WAT (sc-WAT) and interscapular brown adipose tissue (BAT) were dissected. Plasma was obtained after centrifugation of heparinized blood. RNA was extracted (NucleoSpin RNA II; Macherey-Nagel, Düren, Germany) and 0.5 µg RNA was reverse transcribed using random hexamer primers (Applied Biosystems, Foster City, CA, USA). Quantitative real-time PCR reactions were performed on an ABI/Prism-7700 Sequence-Detector System (Applied Biosystems) using reaction mixtures containing 1 ml of complementary DNA, 12.5 ml of TaqMan ® Universal PCR Master Mix (Applied Biosystems), 250 nM probes and 900 nM primers of specific TaqMan ® assay primers for all transcripts (Applied Biosystems). mtDNA quantification and mtDNA-encoded transcripts were assayed using the following TaqMan ® assay ondemand primers: 5′-CCCAACAGGATTAAACTCAG ATGCA-3′ and 5′-CTAGGGTTATGAGAATTAAGAA TATGATTAGGATACCT-3′ for cytochrome b; 5′-GAG CCTCAAACTCCAAATACTCACT-3′ and 5′-GAAC TGATAAAAGGATAATAGCTATGGTTACTTCA-3′ for NADH-dehydrogenase subunit 1; 5′-GGTGCAA TTAATTTTATTACCACTATTATCAACATGA-3′ and 5′-GGCTGTAATAAGTACGGATCAGACA-3′ for cytochrome c oxidase subunit 1. Values were normalized to that of 18S ribosomal RNA using the comparative (2- For HIV-1 transgene expression, the Tat region of the HIV-1 transgene transcript was quantified using an SYBR Green real-time PCR reaction and the primers 5′-ATGGAGCCAGTAGATCCTAGACTA-3′ and 5′-GCTTTGATAGAGAAGCTTGATGAG-3′.
Leptin, insulin, monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), total plasminogen activator inhibitor type-1 (PAI-1), resistin and tumour necrosis factor-α (TNF-α) were quantified in 20 µl of plasma using a multiplex system (Linco Research/Millipore, Saint Charles, MO, USA) and Luminex100ISv2 equipment (Luminex Corp., Austin, TX, USA). Adiponectin was quantified by ELISA (Linco Research/ Millipore) and blood glucose was measured using Accutrend (Roche, St Cugat del Valles, Spain). Statistical comparisons were performed using the Student's t-test.
Results
The mean ±se body weight of Tg26+/-mice (28.08 ±1.58 g) was not significantly different from that of wild-type littermates (28.17 ±0.77g); however, the amount of epididymal WAT was significantly lower in Tg26+/-mice (0.42 ±0.01 g) than in wild-type mice (0.64 ±0.05 g; P<0.05). There were no statistically significant differences in mean ±se sc-WAT between Tg26+/-(0.43 ±0.04 g) and wild-type mice (0.40 ±0.03 g). The amount of interscapular BAT was also similar in both groups (0.21 ±0.01 g in Tg 26+/-mice versus 0.19 ±0.01 g in wild-type mice). When data on tissue weight was referred to body weight, the conclusions were the same.
Plasma adiponectin and leptin levels were significantly lower in Tg26+/-mice than in wild-type mice ( Figure 1 ). There were no statistically significant differences in plasma resistin and PAI-1 levels. TNF-α and IL-6 plasma levels were significantly increased in Tg26+/-mice, consistent with previous reports [9] , and MCP-1 levels were also significantly higher. Glucose and insulin levels were significantly lower in Tg26+/-mice.
HIV-1 transgene transcript was expressed in vs-WAT and sc-WAT to a similar extent, whereas it was less expressed in BAT (Figure 2) . Expression of the master adipogenesis gene, peroxisome proliferator-activated receptor γ (PPARγ), was significantly reduced in both vs-WAT and sc-WAT depots of Tg26+/-mice ( Figure 2) . Expression of the genes for glucose transporter type-4 and adiponectin was also reduced in all WAT depots from Tg26+/-mice. In the vs-WAT of Tg26+/-mice, leptin gene expression was significantly lower and resistin gene expression was not significantly altered. TNF-α and IL-6 gene expression was significantly higher in vs-WAT and sc-WAT from the Tg26+/-mice, respectively. MCP-1 gene expression was higher in all WAT depots from Tg26+/-mice, whereas CD68 expression was unaltered. There were no changes in the expression of adipogenesis-related or inflammation-related genes in BAT of Tg26+/-mice. The expression of thermogenesis-related genes, indicative of the specific BAT versus WAT phenotype (uncoupling protein-1, PPARγ-coactivator-1α and 5′-deiodinase) was significantly increased in BAT of Tg26+/-mice. Finally, mitochondrial DNA (mtDNA) levels and mitochondrial transcripts were unaltered in WAT depots or BAT of Tg26+/-mice.
Discussion
HIV-1 transgene expression in mice caused changes in adipose tissue distribution, systemic adipokine and cytokine levels, and in adipose tissue gene expression that are partially reminiscent of alterations associated with HALS or of alterations observed in HIV-1-infected patients before antiretroviral treatment. Low levels of plasma adiponectin and increased levels of circulating proinflammatory cytokines, as found here in Tg26+/-mice, are typical of HALS patients [10] . The profound reduction in leptin levels in Tg26+/-mice is similar to that reported in some studies in HALS patients [11] . It cannot be explained by overall changes in WAT mass, and reflects specific impairment in leptin synthesis and release by WAT, as a consequence of HIV-1 transgene expression. Glucose and insulin levels were low in Tg26+/-mice, which contrasts with the prodiabetogenic status often observed in patients with HALS [1] , but is in agreement with the enhanced insulin sensitivity, which is often apparent in non-treated, clinically stable, HIV-1-infected patients [12] .
The alterations in gene expression found in adipose tissues from Tg26+/-mice closely follow the pattern of changes in HALS patients, especially the early alterations observed in HIV-1-infected, treatment-naive patients. Similar to the present findings in HIV-1 transgenic mice, reduced expression of PPARγ, the master controller of adipogenesis, and of its targets (glucose transporter type-4 or adiponectin genes), has not only been shown in fat from HALS patients but also in sc-WAT from HIV-1-infected, treatment-naive patients [2] . Moreover, the enhanced expression of proinflammatory cytokines (MCP-1 and IL-6) in sc-WAT from Tg26+/-mice parallels the observations in subcutaneous fat from both treatment-naive patients and those with HALS [2, 13, 14] .
Differential changes in subcutaneous versus visceral fat is a typical feature of HALS [1] . The preferential reduction in the amount of vs-WAT in Tg26+/-mice and unaltered sc-WAT contrasts with the enlargement of visceral fat usually observed in HALS. Epididymal adipose tissue is usually considered as representative of visceral fat in mice, but species-dependent differences in fat distribution between rodents and humans might account for distinct alterations in intra-abdominal adipose tissue [15] .
We found signs of depot-dependent alterations in gene expression as a consequence of HIV-1 transgene expression; for example, TNF-α was induced in vs-WAT, whereas IL-6 was induced only in sc-WAT. These depot-specific changes cannot be the consequence of HIV type-1 transgene differences in HIV-1 transgene expression in mice, as this was similar in vs-WAT and sc-WAT. Whether these depot-specific changes in gene expression are similar to those in patients is not clear. There are a lack of studies in visceral fat from treatment-naive patients and even lipodystrophic patients. A pilot study of visceral fat from patients with overt HALS indicated enhanced expression of proinflammatory cytokines (that is, TNF-α) [14] . Remarkably, increased cytokine expression in WAT in HIV-1 transgenic mice was not associated with modifications in CD68 expression, a macrophage marker. Although macrophage infiltration occurs in subcutaneous fat of HALS patients [16] , this occurs only in association with overt lipodystrophy and, despite local proinflammatory activation, treatment-naive patients do not show evident macrophage infiltration in fat [17] . This observation is fully consistent with the present findings in Tg26+/-mice. We also noted an increase in the expression of genes related to BAT-specific, thermogenesis-related, function in the BAT of Tg26+/-mice. Although BAT is considered more relevant in rodents, the importance of BAT in adult humans has recently undergone a reevaluation [18] . Dorso-cervical fat accumulation, a common feature of HALS, is associated with abnormal activation of the expression of the brown fat marker gene, uncoupling protein-1 [19] . This alteration is another feature of the Tg26+/-model that is consistent with the adipose disturbances in HALS.
The changes in adipose tissue observed in Tg26+/-mice occurred in the absence of mtDNA depletion or dysfunction of mtDNA expression. This is also in agreement with the current concept that mitochondrial toxicity occurs in HALS patients mainly as a consequence of antiretroviral treatment [1] .
In summary, the present study establishes, for the first time, the effects of HIV-1 transgene expression in mice. It is shown that the HIV-1 transgene causes multiple changes in adipose tissue gene expression that are partially consistent with alterations occurring in HIV-1-infected patients that ultimately result in HALS. Importantly, the present data support the notion that HIV-1-infection-related events alter adipose tissue; alterations that might be essential for the development of HALS. It should, however, be taken into account that the present model has several limitations. HIV-1 transgene expression in mice causes mild renal damage at the age at which mice were analysed in the present study, as evidenced, among other signs, by increased plasma creatinine levels [8, 20] . It cannot be excluded that some of the effects observed could be influenced by renal alterations.
Together, the results presented here suggest that Tg26+/-mice might be a suitable model for assessment of the effects of HIV-1 infection on adipose tissue and for experimental assessment of the action of antiretroviral drugs on an HIV-1-infected background.
